TMCnet

BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq: BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today ...

BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform

Data demonstrate progress in each of its MSC-derived programsMELVILLE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.
EurekAlert!

New review identifies four key molecular changes driving spinal disc degeneration

Chronic low back pain, often linked to intervertebral disc degeneration (IVDD), fundamentally stems from the dehydration of the disc’s gel-like center, the nucleus pulposus (NP). This review shifts ...
WTEN

R3 Stem Cell International Publishes Guide to Stem Cell and Exosome Therapy for Back Pain

R3 Stem Cell, the global leader in regenerative therapies, published a recent guide, Stem Cell and Exosome Therapy for Back Pain. The Guide is free to download. Our international centers treat ...